Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) has earned a consensus recommendation of "Buy" from the nine research firms that are presently covering the firm, Marketbeat reports. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $21.43.
CATX has been the subject of a number of analyst reports. Wedbush assumed coverage on Perspective Therapeutics in a research note on Tuesday, October 1st. They set an "outperform" rating and a $25.00 price target for the company. Bank of America assumed coverage on Perspective Therapeutics in a report on Thursday, July 25th. They set a "buy" rating and a $24.00 price target for the company. Cantor Fitzgerald reissued an "overweight" rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Truist Financial started coverage on shares of Perspective Therapeutics in a research report on Wednesday, September 25th. They issued a "buy" rating and a $21.00 price objective for the company. Finally, Royal Bank of Canada dropped their target price on shares of Perspective Therapeutics from $29.00 to $27.00 and set an "outperform" rating on the stock in a research report on Friday, August 16th.
Check Out Our Latest Report on Perspective Therapeutics
Perspective Therapeutics Stock Performance
CATX stock traded down $0.63 during trading on Friday, reaching $12.62. 5,182,972 shares of the stock were exchanged, compared to its average volume of 684,657. The business's 50 day simple moving average is $13.81. Perspective Therapeutics has a twelve month low of $2.20 and a twelve month high of $19.05.
Perspective Therapeutics (NYSE:CATX - Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.04. The business had revenue of $0.53 million for the quarter. Equities analysts predict that Perspective Therapeutics will post -0.87 earnings per share for the current year.
Institutional Trading of Perspective Therapeutics
Several hedge funds have recently made changes to their positions in the company. Victory Capital Management Inc. purchased a new stake in shares of Perspective Therapeutics during the 2nd quarter valued at approximately $117,000. Point72 DIFC Ltd purchased a new stake in shares of Perspective Therapeutics during the second quarter worth $118,000. SG Americas Securities LLC bought a new stake in shares of Perspective Therapeutics during the 3rd quarter valued at $246,000. The Manufacturers Life Insurance Company purchased a new stake in Perspective Therapeutics during the 2nd quarter worth about $188,000. Finally, Iowa State Bank bought a new position in Perspective Therapeutics in the 3rd quarter worth about $254,000. 54.66% of the stock is currently owned by institutional investors.
About Perspective Therapeutics
(
Get Free ReportPerspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
Featured Stories
Before you consider Perspective Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Perspective Therapeutics wasn't on the list.
While Perspective Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.